Guardant Health Stock Performance
| GH Stock | USD 44.42 1.07 2.35% |
The company retains a Market Volatility (i.e., Beta) of 0.97, which attests to possible diversification benefits within a given portfolio. Guardant Health returns are very sensitive to returns on the market. As the market goes up or down, Guardant Health is expected to follow. At this point, Guardant Health has a negative expected return of -0.0838%. Please make sure to check out Guardant Health's sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to decide if Guardant Health performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Guardant Health has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong technical indicators, Guardant Health is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (2.35) | Five Day Return (5.07) | Year To Date Return 39.82 | Ten Year Return 37.95 | All Time Return 37.95 |
1 | Disposition of tradable shares by Joyce Meghan V. of Guardant Health subject to Rule 16b-3 | 05/02/2025 |
2 | Disposition of 23998 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | 05/13/2025 |
3 | Disposition of 8705 shares by Darya Chudova of Guardant Health subject to Rule 16b-3 | 05/15/2025 |
4 | Disposition of 44691 shares by AmirAli Talasaz of Guardant Health at 49.5337 subject to Rule 16b-3 | 05/16/2025 |
5 | Guardant Health Gains as FDA Grants Breakthrough Designation | 06/03/2025 |
6 | Guardant Healths Shield Blood Test Wins Fast Companys 2025 World Changing Ideas Award GH ... | 06/10/2025 |
7 | Disposition of 8088 shares by Clark Ian T of Guardant Health subject to Rule 16b-3 | 06/12/2025 |
8 | Disposition of 250 shares by Tariq Musa of Guardant Health subject to Rule 16b-3 | 06/13/2025 |
9 | Disposition of 2626 shares by Potter Myrtle S of Guardant Health at 49.7 subject to Rule 16b-3 | 06/16/2025 |
10 | Tempus AIs 89 percent Genomics Surge Will the Momentum Keep Building | 06/20/2025 |
11 | Guardant Health, Inc. Receives Average Recommendation of Buy from Analysts | 07/11/2025 |
12 | Guardant Health Inc to Announce Q2 2025 Financial Results GH stock news | 07/14/2025 |
13 | Riassunto Arruolamento del primo paziente nello studio Vanguard del National Cancer Institute per la valutazione del test Shield di rilevazione multitumorale di... | 07/15/2025 |
14 | Erster Patient erfolgreich in Vanguard-Studie des NCI rekrutiert, das den Shield-Multi-Cancer Detection Test von Guardant Health evaluiert | 07/16/2025 |
15 | Acquisition by Hidalgo Medina Manuel of 2784 shares of Guardant Health subject to Rule 16b-3 | 07/17/2025 |
16 | 3 Reasons to Avoid GH and 1 Stock to Buy Instead | 07/23/2025 |
17 | Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test | 07/25/2025 |
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | -261.3 M |
Guardant Health Relative Risk vs. Return Landscape
If you would invest 4,799 in Guardant Health on April 27, 2025 and sell it today you would lose (357.00) from holding Guardant Health or give up 7.44% of portfolio value over 90 days. Guardant Health is generating negative expected returns and assumes 2.8123% volatility on return distribution over the 90 days horizon. Put differently, 25% of stocks are less risky than Guardant on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Guardant Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Guardant Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Guardant Health, and traders can use it to determine the average amount a Guardant Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0298
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GH |
Estimated Market Risk
| 2.81 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Guardant Health is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Guardant Health by adding Guardant Health to a well-diversified portfolio.
Guardant Health Fundamentals Growth
Guardant Stock prices reflect investors' perceptions of the future prospects and financial health of Guardant Health, and Guardant Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guardant Stock performance.
| Return On Equity | -45.84 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 6.11 B | ||||
| Shares Outstanding | 123.89 M | ||||
| Price To Earning | (12.01) X | ||||
| Price To Book | 55.67 X | ||||
| Price To Sales | 7.11 X | ||||
| Revenue | 739.02 M | ||||
| Gross Profit | 474.77 M | ||||
| EBITDA | (390.12 M) | ||||
| Net Income | (436.37 M) | ||||
| Cash And Equivalents | 853.69 M | ||||
| Cash Per Share | 8.35 X | ||||
| Total Debt | 1.34 B | ||||
| Debt To Equity | 4.32 % | ||||
| Current Ratio | 6.18 X | ||||
| Book Value Per Share | (2.03) X | ||||
| Cash Flow From Operations | (239.86 M) | ||||
| Earnings Per Share | (3.39) X | ||||
| Market Capitalization | 5.5 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | (2.58 B) | ||||
| Working Capital | 829.53 M | ||||
| Current Asset | 219.68 M | ||||
| Current Liabilities | 24.24 M | ||||
About Guardant Health Performance
By evaluating Guardant Health's fundamental ratios, stakeholders can gain valuable insights into Guardant Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Guardant Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Guardant Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 89.53 | 68.94 | |
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | 3.12 | 3.28 |
Things to note about Guardant Health performance evaluation
Checking the ongoing alerts about Guardant Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Guardant Health help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Guardant Health generated a negative expected return over the last 90 days | |
| The company generated the yearly revenue of 739.02 M. Annual Net Loss to common stockholders was (436.37 M) with gross profit of 474.77 M. | |
| Guardant Health reports about 853.69 M in cash with (239.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35. | |
| Guardant Health has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test |
- Analyzing Guardant Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guardant Health's stock is overvalued or undervalued compared to its peers.
- Examining Guardant Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guardant Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guardant Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Guardant Health's stock. These opinions can provide insight into Guardant Health's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |